Merck & Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-Negative Breast Cancer

 Merck & Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-Negative Breast Cancer

Merck & Co. Reports Results of Keytruda (pembrolizumab) + CT in P-III KEYNOTE-355 Study as 1L Treatment for Metastatic Triple-Negative Breast Cancer

Shots:

  • The P-III KEYNOTE-355 (part 1 & 2) study involves assessing of Keytruda (200mg, IV, on day 1 of each 21-day cycle) + CT vs PBO + CT in 30 & 847 patients with LA inoperable or mTNBC prior not treated with CT in the metastatic setting
  • The P-III KEYNOTE-355 study resulted in meeting one of its dual 1EPs i.e, improvement in PFS, the safety profile is consistent with the previous studies with no new safety signals. Following the recommendation of DMC, the study will continue its other 1EPs of OS
  • Keytruda is an anti-PD-1 therapy, act by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here to­ read full press release/ article | Ref: Merck | Image: Merck

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post